I. Lucca, J. Leow, S. Shariat, and S. Chang, Diagnosis and Management of Upper Tract Urothelial Carcinoma, Hematology/Oncology Clinics of North America, vol.29, issue.2, pp.271-288
DOI : 10.1016/j.hoc.2014.10.003

V. Margulis, S. Shariat, S. Matin, A. Kamat, R. Zigeuner et al., Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration, Cancer, vol.12, issue.pt 1, pp.1224-1233, 2009.
DOI : 10.1002/cncr.24135

G. Verhoest, S. Shariat, T. Chromecki, J. Raman, V. Margulis et al., Predictive factors of recurrence and survival of upper tract urothelial carcinomas, World Journal of Urology, vol.54, issue.27, pp.495-501, 2011.
DOI : 10.1007/s00345-011-0710-3
URL : https://hal.archives-ouvertes.fr/inserm-00604856

G. Xiong, J. Liu, Q. Tang, Y. Fan, D. Fang et al., Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma, Epigenomics, vol.7, issue.5, pp.733-744
DOI : 10.2217/epi.15.34

C. Varley, E. Bacon, J. Holder, and J. Southgate, FOXA1 and IRF-1 intermediary transcriptional regulators of PPAR??-induced urothelial cytodifferentiation, Cell Death and Differentiation, vol.62, issue.1, pp.103-114, 2009.
DOI : 10.1016/j.ydbio.2007.01.010

D. Degraff, P. Clark, J. Cates, H. Yamashita, V. Robinson et al., Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation, PLoS ONE, vol.77, issue.5, p.36669
DOI : 10.1371/journal.pone.0036669.t003

O. Reddy, J. Cates, L. Gellert, H. Crist, Z. Yang et al., Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. The American journal of pathology, pp.1385-1395, 2015.

D. Lee, E. Xylinas, M. Rieken, F. Khani, T. Klatte et al., Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma, European Urology, vol.66, issue.2, pp.379-385, 2014.
DOI : 10.1016/j.eururo.2013.12.008
URL : https://hal.archives-ouvertes.fr/hal-01064294

D. Degraff, M. Grabowska, T. Case, X. Yu, M. Herrick et al., FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype investigation, Laboratory, issue.7, pp.94726-739, 2014.

J. Mirosevich, N. Gao, A. Gupta, S. Shappell, R. Jove et al., Expression and role of Foxa proteins in prostate cancer, The Prostate, vol.6, issue.10, pp.661013-1028, 2006.
DOI : 10.1002/pros.20299

J. Mirosevich, N. Gao, and R. Matusik, Expression of Foxa transcription factors in the developing and adult murine prostate, The Prostate, vol.20, issue.4, pp.339-352, 2005.
DOI : 10.1002/pros.20131

E. Reisenbichler, S. Lester, A. Richardson, D. Dillon, A. Ly et al., Interobserver Concordance in Implementing the 2010 ASCO/CAP Recommendations for Reporting ER in Breast Carcinomas: A Demonstration of the Difficulties of Consistently Reporting Low Levels of ER Expression by Manual Quantification, American Journal of Clinical Pathology, vol.140, issue.4, pp.487-494
DOI : 10.1309/AJCP1RF9FUIZRDPI

C. Bartosch, S. Monteiro-reis, D. Almeida-rios, R. Vieira, A. Castro et al., Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium, Oncotarget, vol.2016, issue.72, pp.1144-1154

J. Harvey, G. Clark, C. Osborne, and D. Allred, Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer, Journal of Clinical Oncology, vol.17, issue.5, pp.1474-1481, 1999.
DOI : 10.1200/JCO.1999.17.5.1474

M. Rink, H. Fajkovic, E. Cha, A. Gupta, P. Karakiewicz et al., Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma, European Urology, vol.61, issue.4, pp.61854-855
DOI : 10.1016/j.eururo.2011.12.055

D. Degraff, J. Cates, J. Mauney, P. Clark, R. Matusik et al., When urothelial differentiation pathways go wrong: Implications for bladder cancer development and progression, Urologic Oncology: Seminars and Original Investigations, vol.31, issue.6, pp.31802-811, 2013.
DOI : 10.1016/j.urolonc.2011.07.017

S. Rebouissou, I. Bernard-pierrot, A. De-reynies, M. Lepage, C. Krucker et al., EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype al: Genomic Characterization of Upper Tract Urothelial Carcinoma, Science translational medicine 2014 European urology, vol.6, issue.2446, pp.68970-977, 2015.